A Phase 1b/2 Study of Duvelisib in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Latest Information Update: 12 Apr 2023
At a glance
- Drugs Duvelisib (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Secura Bio
Most Recent Events
- 14 Mar 2023 Status changed from suspended to discontinued. The study was terminated due to low enrollment.
- 15 Mar 2021 Planned End Date changed from 1 May 2022 to 1 Apr 2021.
- 15 Mar 2021 Status changed from recruiting to suspended.